Ablynx, of Ghent, Belgium, appointed Eva-Lotta Allan chief business officer.
Abraxis BioScience Inc., of Los Angeles, appointed Frank Harmon executive vice president, global operations; Sam Trippie senior vice president, manufacturing; and Jeff Silverman vice president, operations integration and new technology development. The company also named others to its executive management team: Richard Maroun as chief administrative officer; Thomas Silberg as executive vice president, commercial operations and operational excellence; John Weidenbruch as general counsel and assistant corporate secretary; Bruce Wendel as executive vice president, corporate development; and Ronald Pauli as interim chief financial officer.
Abt Associates, of Cambridge, Mass., appointed Kay Larholt vice president and executive director, biostatistics/epidemiology.
Acadia Pharmaceuticals Inc., of San Diego, appointed Roger Mills executive vice president, development.
Affibody AB, of Stockholm, Sweden, appointed Ulf Boberg CEO.
Affymax Inc., of Palo Alto, Calif., appointed Kay Slocum senior vice president of human resources.
Allos Therapeutics Inc., of Westminster, Colo., appointed James Caruso executive vice president, chief commercial officer.
Alnylam Pharmaceuticals Inc., of Cambridge, Mass., appointed Saraswathy Nochur vice president, regulatory affairs.
Alpharma Inc., of Fort Lee, N.J., appointed Dean Mitchell president and CEO.
Altair Nanotechnologies Inc., of Reno, Nev., appointed Pierre Lortie to its board.
Altus Pharmaceuticals Inc., of Cambridge, Mass., appointed Burkhard Blank senior vice president medicine, regulatory affairs and project management.
Amphion Innovations plc, of New York, said its partner company, Motif BioSciences Inc., named Zaki Hosny deputy chairman and CEO.